Amy Stulick

Staff Reporter (Health Care, Law)

Email: astulick@sfvbj.com
Phone: 818-316-3121 Extension: 112

Recent Stories

Woodbury University Receives Grant Installment as Hispanic-Serving Institution

Woodbury University has received a $600,000 grant from the U.S. Department of Education as a Hispanic Serving Institution.

Second Sight Resumes Study

Second Sight Medical Products has resumed its early feasibility study for the Orion, its next-generation visual prosthetics system, after being put on hold for seven months because of COVID-19.

Medical Device Maker Gets $98 Million

Agoura Hills medical device company V-Wave has nabbed $98 million for its Series C round of financing, paving the way for clinical trials and Food and Drug Administration clearance, according to a statement from the company late Tuesday.

Social Impact Fund Invests in ConsejoSano

North Hollywood health care software company ConsejoSano has received an investment from the Bernard J. Tyson Impact Fund.

Bar Association Elects David Jones as President

The San Fernando Valley Bar Association on Thursday formally announced its new board of trustees and officers, led by David Jones as president.

Tease photo

Amgen, Eli Lilly to Manufacture COVID-19 Treatments

Biopharma giants Amgen Inc. and Eli Lilly on Thursday announced an antibody manufacturing collaboration for potential COVID-19 treatments.

Amgen Selects Bay Area Startups for Big Ticket Program

Amgen Inc. on Tuesday announced its Golden Ticket winners — startup companies BigHat Biosciences and Trilo Therapeutics.

Law Facilitates Retirement Fund Withdrawals in COVID Crisis

Employees looking to draw from retirement funds to stay afloat during the pandemic can now do so without penalty because of a new law.

West Hills Hospital Closes Obstetrics Unit After 'Significant Decline' in Births

West Hills Hospital will close its obstetrics program effective Nov. 1, the organization announced earlier this month.

FDA Approves Atara Biotherapeutics to Begin Tumor Trial

Atara Biotherapeutics has received the U.S. Food and Drug Administration’s green light to start clinical trials for its next-generation CAR T therapy.

More stories >>